A Phase 3 trial investigating nivolumab for the prevention of recurrent Stage IIB/C melanoma completed its primary endpoint on 2022-06-28. The study reported a significant reduction in recurrence risk, with a hazard ratio of 0.42 (p=0.0001) compared to placebo. This suggests a substantial benefit for patients at high risk of recurrence after complete resection.

Background

Nivolumab is an immunotherapy investigated for its role in preventing recurrence in patients with Stage IIB/C melanoma. These patients have undergone complete resection but remain at high risk for disease recurrence.

Trial design

This was a Phase 3 study (NCT04099251) with an enrollment of 790 adult and pediatric participants. The trial focused on individuals with Stage IIB/C melanoma who had undergone complete resection and had no evidence of disease but were at high risk for recurrence. Participants were randomized to receive either nivolumab adjuvant immunotherapy or placebo.

Key results

The trial's primary analysis reported a hazard ratio (HR) of 0.42 (95% Confidence Interval: 0.3 to 0.59) with a p-value of 0.0001, indicating a statistically significant reduction in recurrence risk for the nivolumab arm compared to placebo. This analysis was performed using a Cox regression method.

Regarding other measured outcomes:

  • The median duration of treatment on next line therapy was 4.17 Months for the nivolumab group and 11.14 Months for the placebo group.
  • A total of 502 participants in the nivolumab group experienced adverse events (AEs), compared to 229 participants in the placebo group.
  • Further adverse event data showed 115 participants in the nivolumab group and 32 participants in the placebo group experienced AEs.

What this means

The statistically significant hazard ratio of 0.42 strongly suggests that nivolumab is effective in reducing the risk of recurrence for patients with resected Stage IIB/C melanoma. This finding is crucial for a population at high risk of disease return. The difference in duration of next-line therapy might reflect differing disease progression patterns between the groups, with the placebo group potentially progressing earlier and thus starting next-line therapy sooner and for a longer duration. The adverse event data indicates a higher incidence of AEs in the nivolumab arm, which is a common consideration for immunotherapies, and would require further detailed analysis of severity and type.

Source

The primary completion status and results for this study were posted on 2022-06-28 on ClinicalTrials.gov, an official database of clinical studies. The full details are available on clinicaltrials.gov under the identifier NCT04099251.